Running title; HOXA9/SMAD4 interaction prevents leukemia ABSTRACT We studied leukemic stem cells (LSCs) in a Smad4 -/mouse model of acute myelogenous leukemia (AML) induced either by the HOXA9 gene or by the fusion oncogene NUP98-HOXA9. While HOXA9-SMAD4 complexes accumulate in the cytoplasm of normal hematopoietic stem-and progenitor cells (HSPCs) transduced with these oncogenes, there is no cytoplasmic accumulation of HOXA9 in Smad4 -/-HSPCs and as a consequence increased levels of HOXA9 accumulate in the nucleus leading to increased immortalization in vitro. Loss of Smad4 accelerates the development of leukemia in vivo due to an increase in transformation of HSPCs.
INTRODUCTION
HOXA9 is the most highly expressed Homeobox (HOX) gene in the hematopoietic stem cell (HSC) compartment of bone marrow and is downregulated upon differentiation. 1, 2 Retrovirally enforced overexpression of HOXA9 gene in bone marrow cells enhances expansion of hematopoietic stem cells in vitro. 3 HOXA9 is also the most commonly deregulated HOX gene in leukemia and constitutive expression of the HOXA9 gene might be a common mechanism that unifies diverse initiating events in acute myeloid leukemia (AML) and is associated with a poor clinical prognosis. 4 The leukemogenic potential of HOXA9 was directly demonstrated by the development of AML in mouse bone marrow transplantation chimeras that received a graft of primitive HSCs engineered by retroviral gene transfer to overexpress HOXA9. Murine transplantation studies showed that forced expression of HOXA9 in hematopoietic precursors results in a significant transformation of primitive hematopoietic cells and leukemia. 5 HOXA9 is also directly involved in human leukemia caused by the translocation t(7;11)(p15;p15) of HOXA9 with the gene encoding NUP98, a nucleoporin protein. 6, 7 Expression of this fusion protein enforced expression of HOXA9 target genes 8 and immortalized hematopoietic myeloid progenitors. 9 Similarly, overexpression of the NUP98-HOXA9 fusion protein immortalizes murine hematopoietic progenitor cells and results in a myeloproliferative disorder (MPD) in bone marrow transplantation experiments with development of lethal AML in a fraction of the animals. 10 Transforming growth factor beta (TGF-β) generates an antiproliferative effect on cells by modulating expression of genes involved in cell cycle regulation and apoptosis. 11 TGF-β-induced activation of p15 and the Cip/Kip family of CDKIs (p21, p27, p57) has been observed in hematopoietic progenitors. [12] [13] [14] The mechanisms behind TGF-β induced growth arrest in normal hematopoiesis are more complex, since TGF-β potently induces apoptosis of primitive murine hematopoietic progenitor cells, 15 while reduced differentiation capacity without affecting viability of early hematopoietic progenitors has also been observed after treatment with TGF-β. 16, 17 It has been recently described that TGF-β signaling shows differential regulation in vivo between repopulating HSCs subtypes that can be prospectively isolated. 18 For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Members of the TGF-β family are potent tumor suppressors and malignant cells can acquire resistance to the antiproliferative effect of TGF-β by different mechanisms, including defects in TGF-β receptors and mutational inactivation of downstream effectors of the TGF-β signaling pathway, as reported in several malignancies. 19, 20 Deregulation of TGF-β signaling is also well recognized in leukemogenesis. 21, 22 Loss-of-function mutations that disrupt the TGF-β pathway involving the Smad4 gene 23, 24 or the TGF-BR2 gene 25, 26 have also been reported in patients with AML. Furthermore using ultra-dense array comparative genomic hybridization on AML genomes, the Smad4 gene was frequently found to be deleted in AML. 27 Finally, through in vitro studies, it has been demonstrated that SMAD4 physically binds to and affects the function of HOXA9. 28 All these findings suggest that Smad4 might be an AML-associated gene.
While the studies cited above suggest a negative regulatory role for Smad4 in the leukemogenesis mediated by HOXA9, it has not been demonstrated whether Smad4 can prevent or block the initiation and/or maintenance of leukemia in vivo. Using an inducible Smad4 knockout (Smad4 -/-) mouse model where the Smad4 gene is deleted in hematopoietic stem cells, 29 we asked whether regulatory circuits controlled by Smad4 provide a protective mechanism in primitive hematopoietic cells (HSPCs; hematopoietic stem-and progenitor cells) to prevent the initiation of leukemia.
MATERIALS AND METHODS

Isolation of bone marrow cells from Smad4 -/and Wt mice
Animal experiments, isolation of bone marrow cells and purification (Lindepletion) of hematopoietic stem and progenitors cells (HSPCs) were performed following previously described protocols, 29 approved by the Lund University Animal Ethical Committee.
Retroviral transduction
HOXA9, NUP98-HOXA9, MOZ-TIF2 and AML1-EVI1 (MSCV-IRES-EGFP) retroviral vectors were transfected into Phoenix Ampho cells (Nolan lab; Stanford University, Palo Alto, CA) and supernatants were harvested for transduction of HSPCs.
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Colony-forming unit assay
HSPCs-transduced cells were plated into methylcellulose (MethoCult, Stem Cell Technologies). M3434 containing 15% of FBS was used with or without addition of 10 ng/ml of recombinant TGF-β (Peprotech). M3236 was used as a TGF-β-free medium and was supplemented with 50 ng/ml mSCF, 10 ng/ml mIL-3, 50 ng/ml hIL-6 and, where appropriate, 20 nM of the TGF-β receptor kinase inhibitor II (Calbiochem). Ten days later, colony-forming unit were counted and replated for three-round of plating.
Limiting dilution assay
Limiting dilution assay was done by plating transduced cells in 96-well culture plates, in SFEM medium supplemented with mSCF, mIL-3 and hIL-6. Percentage of positive wells where expansion of cells was observed was count after 10-days of culture.
BM transplantation
To induce leukemia, 2 x 10 5 transduced Lin -HSPCs (Ly5.2) were mixed with 2 x 10 5 support BM cells (Ly5.1) and transplanted into the tail vein of lethally irradiated (9 Gy) C57BL/6 x B6SJL recipient mice (Ly5.1/Ly5.2). For quantification of LICs, 1 x 10 4 , 1 x 10 3 , 1 x 10 2 leukemic cells from primary recipients were mixed with 2 x 10 5 support BM cells and transplanted into the tail vein of lethally irradiated secondary recipient mice.
Cloning of MH1, transduction and BM transplantation of MH1-expressing cells
Four portions of the MH1 part of the human Smad4 cDNA were amplified by PCR with primers to introduce a FLAG (5´-DYKDDDDK-MH1) and were cloned into a retroviral vector expressing RFP (pRetroX-IRES-DsRedExpress Vector, Clontech, CA, USA).
HSPCs were co-transduced with NUP98-HOXA9 (GFP + ) and MH1 (RFP + ), cotransduced cells (GFP + /RFP + ) were sorted (Diva, Becton Dickinson) and transplanted into the tail vein of lethally irradiated recipient mice.
Hematology of peripheral blood
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Erythrocytes were lysed with NH 4 Cl and remaining cells were stained with conjugated antibodies for FACS analysis. Hematologic parameters were monitored to control the development of leukemia (KX-21N, Sysmex).
Flow cytometry
For lineage depletion BM cells were stained with a cocktail of antibodies; rat anti-mouse B220, Gr1, Mac1, CD4, CD5, CD8, Ter119 (Becton Dickinson) and goat anti-rat Tricolor antibody (Caltag Lab, Burlingame, CA). For the lineage staining analysis, Sca-1 PE-Cy5.5, c-Kit APC, CD34 PE-Cy7, Flt3-PE antibodies (Becton Dickinson) were used. 7amino-actinomycin D (7-AAD) was used for detection of non-viable cells (Sigma, St Louis, MO). BrdU Flow Kit was used for cell cycle analysis (Becton Dickinson). Stained cells were run thought a FACS Calibur or a FACS Canto II (Becton Dickinson) and the subsequent data were analyzed with FlowJo software (Tree Star, Ashland, OR).
Patient's samples
BM samples were used from AML patients containing the chromosomal translocation t(7;11)(p15;p15), resulting in the generation of NUP98-HOXA9 fusion genes. The presence of a NUP98-HOXA9 rearrangement was verified by either FISH or reversetranscriptase PCR. In addition, BM samples from AML patients showing either high or low expression in HOXA9 and normal human BM samples were analyzed. Samples were obtained from patients after informed consent in accordance with the Declaration of Helsinki.
Western blot
Cytoplasm was dissociated from nucleoplasm following a previously described protocol. 30 Laemmli buffer (BioRad) was added on nucleoplasm fraction (pellet) and cytoplasmic fraction (supernatant) was diluted 1:1 in Laemmli buffer. Antibodies used for Western blot were mouse anti-SMAD4 (clone Sc-7966, Santa Cruz Biotechnology), rabbit anti-SMAD4 (1:300, clone EP618Y, Abcam), anti-HOXA9 (clone 07-178, Upstate biotechnology), anti-NUP98 antibody (2H10, Sigma), anti-CASP3 (clone CPP32, Becton
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Dickinson), anti-ACTIN (clone Ab-5, Becton Dickinson) and anti-LAMIN-A (clone L1293, Sigma). After blotting with an HRP-conjugated secondary antibody, chemiluminescence was detected using the enhanced chemiluminescence (ECL) Advance Western blot detection kit (Amersham Biosciences). Gel images were analyzed using Image J (NIH) for quantification.
Immunostaining
After binding on poly-L-Lysine treated slides (Menzel-Gläser), cells were air-dried, fixed with PFA 4% and permeabilized with 1x Triton X100. HSPCs were washed. Rabbit anti-SMAD4 (1:300, clone EP618Y, Abcam) and mouse anti-HOXA9 (1:300, clone 2A11-2D2, Abnova) antibodies were applied with 5% donkey serum for 12h at 4°C. After washes in PBS, secondary donkey anti-mouse 555 and donkey anti-rabbit 488 antibodies (1:500, Alexa Fluor, Jackson ImmunoResearch) were applied with 5% donkey serum for 2h. For SMAD4 nuclear translocation cells were treated 12h with the recombinant TGF-β 
Immunoprecipitation
For analysis of SMAD4-HOXA9 complexes, 10 7 cells were lysed and precleared with protein G (Life Sciences). The lysate was immunoprecipitated with the SMAD4 antibody and loaded onto a PAGE without SDS to analyze proteins in the native condition. The immunoblot was incubated with the anti-SMAD4 or the anti-HOXA9 antibodies. To analyze the binding of the different portions of MH1, 2 x 10 6 sorted cells expressing NUP98-HOXA9 and MH1 were lysed. The lysate was immunoprecipitated with the anti-FLAG M2 antibody (Stratagene) and the immunoblot analyzed on PAGE-SDS with an anti-HOXA9 antibody.
TUNEL assay
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Chromatin immunoprecipitation
Proteins were crosslinked with 1% formaldehyde and chromatin was sonicated to an average length of DNA fragment sizes of 0.5-1.5 kb. After cell lysate preclearing with protein G, the lysate was immunoprecipitated with the SMAD4 antibody or mouse control IgG antibody. Immune complexes were collected with protein G beads for 1h.
Beads were then washed and incubated with RNase and Proteinase K. DNA was pelleted and immunoprecipitated chromatin was assayed by semi-quantitative PCR.
RNA extraction, reverse transcription and real-time PCR
RNA extraction, cDNA synthesis and real-time PCR were performed following a previously described protocol, 30 using the ABI7900HT system (Applied Biosystems).
Statistical analysis
All data are expressed as the means ± SEM. We assessed differences between the groups by Student's unpaired t-test. Statistical analysis of survival curves were performed using the Mantel Haenszel logrank test.
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RESULTS
The immortalizing function of HOXA9 and NUP98-HOXA9 is increased in Smad4 -/hematopoietic primitive cells
To ask whether there is a definite functional role for Smad4 in immortalization of primary hematopoietic cells by HOXA9 and NUP98-HOXA9, we serially replated hematopoietic colonies (colony-forming unit; CFU) from bone marrow cells transduced with these oncogenes. We purified Lincells, which are enriched for hematopoietic stem cells and more differentiated committed myeloid progenitor cells (HSPCs; hematopoietic stem-and progenitor cells) and transduced this population with HOXA9 or NUP98-HOXA9 retroviral constructs. To assess the efficiency in the immortalization of wild type (Wt) and Smad4 -/-HSPCs, we used a semi-solid medium that contains 15% of fetal bovine serum (FBS) supplemented with IL-3, IL-6, SCF. The cloning efficiency was markedly increased in Smad4 -/cells ( Figure 1A) . Only CFU-GM colonies were immortalized by HOXA9 and NUP98-HOXA9 oncogenes while other hematopoietic colonies (CFU-GEMM, CFU-E, CFU-M and CFU-G) were not maintained through multiple passages (Supplementary Figure 1) . When we transduced hematopoietic cells with two completely different oncogenes (MOZ-TIF2, AML1-EVI1), no rapid expansion of immortalized progenitors was seen in Smad4 -/marrow compared with Wt ( Supplementary Figure 2) , indicating that the Smad4 -/effect is HOX-dependant and probably related to previously described interaction between SMAD4 and HOXA9. 28 A significant decrease in size of the CFU-GM colonies formed by Smad4 -/cells was observed in the semi-solid medium plates, suggesting a difference in composition ( Figure 1B) . Morphology analysis confirmed that Smad4 -/cells were more immature, as Giemsa staining showed an increase in the number of myeloblasts in the Smad4 -/colonies ( Figure 1C) . Additionally, FACS analysis demonstrated an increase in the proportion of the c-Kit + primitive sub-population in the Smad4 -/colonies ( Figure 1D) , and increased cell cycling capacity of c-Kit + Smad4 -/transduced cells (Figure 1E) . It is thus clear that Smad4 deficiency induces primitive fate options in HOXA9 and NUP98-HOXA9 transduced HSPCs. 
Reduced immortalization of Wt primitive hematopoietic cells by HOXA9 or NUP98-HOXA9 does not require the canonical function of SMAD4
Administration of recombinant TGF-β (10 ng/ml) to the medium induced the nuclear translocation of SMAD4 (Supplementary Figure 3) , which led to a reduction/block in the immortalization of Wt primitive hematopoietic cells expressing the oncogenes (Figure 1F) . This clearly shows that TGF-β signaling is not impaired in Wt We next assessed the serial replating of hematopoietic colonies using a semi-solid medium free of FBS (MethoCult M3236) supplemented with a TGF-β receptor kinase inhibitor to prevent activation of hematopoietic cells from the autocrine TGF-β production. We asked whether the immortalization of Wt transduced HSPCs would reach the immortalization frequency observed for Smad4 -/-HSPCs by blocking TGF-β signaling. Interestingly, we observed that the immortalization of TGF-β receptor-blocked Wt cells was still reduced, compared to Smad4 -/cells ( Figure 1F ). By limiting dilution assay in 96-well plate, in DMEM medium (free of TGF-β) supplemented with the TGF-β receptor kinase inhibitor, the growth capacity of HOXA9-and NUP98-HOXA9transduced Smad4 -/cells was increased ~8-fold compared to Wt cells ( Figure 1G) .
The Smad4 signaling pathway functions to transduce signals downstream of the TGF-β family of ligands, including the activation of the TGF-β receptor, and the receptors for Activins and bone morphogenetic proteins (BMPs). 31 We could exclude implication of the BMP pathway since administration of recombinant BMPs (mix of BMP 2, 4 and 7 at 10 ng/ml each) did not block growth of Wt transduced cells overexpressing HOXA9 or NUP98-HOXA9. However, administration of recombinant Activin A (10 ng/ml) blocked growth of Wt transduced cells (Supplementary Figure  4A ). To avoid that other activators of Smad4 signaling were involved, we also tested an inhibitor of endogenous Activin and TGF-β signaling (SB-431542) to inhibit both these pathways that can activate Smad4 signaling. Here again, we observed that immortalization of Wt transduced HSPCs never reached the immortalization frequency observed for Smad4 -/-HSPCs (Supplementary Figure 4B) . We therefore concluded that the activation of the canonical Smad4 signaling pathway is not required for the growthreducing effect of HOXA9/NUP98-HOXA9-transduced progenitors mediated by SMAD4.
Increased SMAD4 protein levels in human AML samples with high levels of the HOXA9 protein
Our findings that Smad4 deficiency leads to enhanced immortalization of Smad4 -/cells in vitro urged us to gain insight into the molecular mechanisms by which aberrant TGF-β signaling may participate in leukemogenesis in patients of NUP98-HOXA9 induced AML. Western blot analysis of BM cells derived from patients with NUP98-HOXA9-related AML had highly activated HOXA9 expression, since NUP98-HOXA9 enforces strong expression of the cellular HOXA9 gene. 9 Intriguingly, we discovered that SMAD4 protein levels were strongly upregulated and that this increased expression unexpectedly correlated with the endogenous HOXA9 protein expression (Figure 2A ).
Since several AML leukemias exhibit increased expression of a subset of HOX genes, including HOXA9, 4 we examined additional AML patient samples by Western blot analysis and observed that increased SMAD4 protein levels were restricted to AML samples with increased levels of the endogenous HOXA9 protein, and there was a correlation between the levels of the two proteins (Figure 2A) . SMAD4 expression could not be correlated to FAB subtypes of AML samples used in the study and consequently can not reflect different SMAD4 levels at differing stages of myeloid maturation. We could demonstrate the co-localization of HOXA9 and SMAD4 in primary human AML blasts showing high levels of HOXA9 (Supplementary Figure 5 ).
SMAD4/HOXA9 stabilization in the cytoplasm of primitive hematopoietic cells immortalized by HOXA9 or NUP98-HOXA9
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Using Western blot analysis, we analyzed the intracellular level of SMAD4 and HOXA9 in mouse HSPCs immortalized by HOXA9 or NUP98-HOXA9 and importantly observed that both proteins were increased and present at correlated levels in the cytoplasmic fraction, whereas no correlation was detectable in the nucleus (Figure 2B) .
Increased expression of the SMAD4 protein cannot be explained by an increase in the transcriptional activation of the Smad4 mouse gene, since there was no upregulation of the Smad4 transcripts in cells expressing HOXA9 or NUP98-HOXA9 (Supplementary Figure 6) . Importantly, the SMAD4 protein expression was not found increased in HSPCs purified from Wt cells transduced with two control oncogenes (MOZ-TIF2, Figure 7) . We furthermore observed increased amount of SMAD4 when Cos7 cells were transduced with HOXA9 (Supplementary Figure 8 ). This suggests that HOXA9 can stabilize SMAD4 in a cell line and not only in progenitors that are in differentiation flux.
Since HOXA9 can physically bind to SMAD4, 28 we asked whether SMAD4 is accumulated in cells. Indeed immunoprecipitation of SMAD4 confirmed that the protein was mainly (>80%) complexed to HOXA9 in HSPCs either immortalized by HOXA9 or NUP98-HOXA9 (Figure 2C) . The reverse immunoprecipitation also confirmed the SMAD4-HOXA9 complexes in Wt HSPCs immortalized by forced expression of HOXA9 or NUP98-HOXA9 (Figure 2D) . We next investigated intracellular immunostaining and importantly observed that only primitive hematopoietic cells (Linpurified) showed predominant cytoplasmic expression of SMAD4 and HOXA9, while more differentiated cells (Lin + purified) showed nuclear localization of HOXA9 (Figure 3A and Supplementary Figure 9 ). We confirmed by confocal microscopy the co-localization of SMAD4 and HOXA9 in the cytoplasm of Wt primitive hematopoietic cells immortalized by HOXA9 or NUP98-HOXA9 (Figure 3B) .
Taken together our data are consistent with a mechanism that involves HOXA9/SMAD4 stabilization/accumulation in the cytoplasm of primitive hematopoietic cells immortalized by HOXA9 or NUP98-HOXA9.
Increased concentration of HOXA9 was observed in the nucleus of Smad4 -/primitive hematopoietic cells immortalized by HOXA9 or NUP98-HOXA9
We next analyzed if this stabilization/accumulation might be a mechanism where SMAD4 binds HOXA9 to the cytoplasm to protect against accumulation of HOXA9 protein in the nucleus. The Smad4 -/model represents a versatile tool since the HOXA9 stabilization is not possible without endogenous SMAD4. Using immunostaining we clearly observed that HOXA9 was largely dispersed in immortalized Smad4 -/-HSPCs We conclude that in Wt HSPCs, SMAD4 stabilizes HOXA9 to the cytoplasm to protect against increased exposure of HOXA9/NUP98-HOXA9 in the nucleoplasm. This mechanism explains why immortalization of transduced hematopoietic progenitors was markedly increased in Smad4 -/cells, as previously observed. (Figure 4E) .
Loss of Smad4 increases the frequency of leukemia stem cells and increases bone marrow transformation in mice
Mice transplanted with Smad4 -/-HSPCs show an accelerated HOXA9-induced transformation of BM, illustrated by a substantial accumulation of donor-derived LK population in BM already 22 weeks following transplantation (Figure 5A) . Accordingly, a larger fraction of mice transplanted with Smad4 -/transduced-cells succumbed more rapidly to AML (Figure 5B) . In addition, the pre-leukemic myeloproliferative disease that NUP98-HOXA9 induces in mice 10 was more pronounced in the Smad4 -/background ( Figure 5C ). Only the total WBC level was affected, whereas other constituents of peripheral blood, red blood cells, hematocrit and hemoglobin remain constant overtime.
Next, we asked whether the frequency of leukemia stem cells (LSCs) capable of enhanced self-renewal and responsible for the maintenance of leukemia was affected in the Smad4 null background. Therefore, 10,000 leukemic cells generated in primary recipient mice were transplanted into secondary recipients, and we observed that the time to onset of leukemia was dramatically reduced for Smad4 -/leukemias (Figure 5D ).
Therefore, we tested the repopulative capacity of LSCs using the limiting dilution transplantation assay to analyze the proportion of secondary transplanted mice that developed leukemia. We observed that the HOXA9-and NUP98-HOXA9-transformed Smad4 -/leukemic cell population was 11-and 14-fold enriched for leukemia-initiating cells (LICs) respectively, compared to Wt leukemic cells (Figure 5E ). Hence, we conclude that the fraction of LSCs was increased in the Smad4 -/background. Compared to normal BM, we also observed increased SMAD4 protein levels in murine BM Wt leukemic cells generated under forced expression of HOXA9, with a predominant For personal use only. on November 16, 2017. by guest www.bloodjournal.org From expression of SMAD4 and HOXA9 in the cytoplasm of Wt leukemic cells, while HOXA9 was found dispersed in Smad4 -/leukemic cells (Supplementary Figure 11) .
The induced AML features were identical in Wt and Smad4 -/hematopoietic cells, and no difference was observed in the pathology of the disease. Myeloblastic cells were predominantly c-Kit + Mac1 + and the mice exhibited similar splenomegaly and equivalent levels of white blood cells in peripheral blood (Supplementary Figure 12) . Infiltration of leukemic cells in extrahematopoietic tissues was also found to be comparable (Supplementary Figure 13) .
The co-expression of a truncated SMAD4 blocks immortalization of primitive hematopoietic cells
Next, we developed an approach to activate the TGF-β pathway by changing the subcellular distribution of the endogenous SMAD4 protein accumulated in the cytoplasm of HSPCs transduced with HOXA9 or NUP98-HOXA9. To this end, we first identified the best competitor by generating different constructs (Figure 6A and Supplementary   Figure 14 ) that enable expression of diverse portions of the MH1 domain of SMAD4, binding HOXA9. 28 All the retroviral vectors (RFP + ) were tested by co-expression together with the NUP98-HOXA9 oncogene (GFP + ). Co-transduced GFP + RFP + cells were sorted by FACS (Supplementary Figure 15) to assess the effect of MH1 overexpression by CFU assay. Interestingly, one specific portion of SMAD4 (MH1-c encoding a peptide of 20aa) dramatically reduced immortalization capacity of NUP98-HOXA9 (Figure 6B) . The insensitivity of Smad4 -/cells shows notably that the specificity of this effect is SMAD4 dependent.
The co-expression of a truncated SMAD4 modifies the subcellular distribution of SMAD4 and activates apoptosis
Compared to the other truncated MH1 portions tested, the increased effect of MH1-c was correlated to its capacity to bind HOXA9, as assessed by FLAG immunoprecipitation of the different portions of MH1 (Figure 6C) . The increased effect of MH1-c was furthermore correlated to its capacity to induce apoptosis, as assessed by upregulation of the pro-CASPASE 3, activation of the cleaved-CASPASE 3 and a For personal use only. on November 16, 2017. by guest www.bloodjournal.org From reduction in BCL2 expression ( Figure 6D) . Using the TUNEL assay, we confirmed that >80% of hematopoietic cells expressing MH1-c were apoptotic (Figure 6E) .
To understand the mechanism behind the effect of MH1-c, we looked at the localization of SMAD4 by immunostaining. Expression of MH1-c was observed to induce a robust nuclear translocation of the SMAD4 protein, while SMAD4 remained accumulated in the cytoplasm of cells transduced with the empty control vector (MH1-e) ( Figure 6F) . The nuclear translocation of SMAD4 is generally thought to be liganddependent. Therefore, we tested production of TGF-β by the transduced hematopoietic cells and could confirm the autocrine production of TGF-β by HOXA9-and NUP98- Figure 16) . MH1-c disrupts the physical interaction between HOXA9 and SMAD4, the SMAD4 subcellular distribution pattern was modified and the nuclear translocation clearly activated the TGF-β pathway, which was confirmed by an increased presence of SMAD4 on the chromatin of cells transduced with MH1-c as assessed by chromatin immunoprecipitation using the anti-SMAD4 antibody (Figure 6G ) and by an increase in transcription of specific targets of the Smad4 pathway (p15, p21 and p27), involved in growth control (Figure 6H) .
HOXA9-transduced cells (Supplementary
The co-expression of a truncated SMAD4 blocks the leukemic transformation of primitive hematopoietic cells in vivo
Next, we asked whether MH1-c might affect the development of leukemia in vivo.
When HSPCs were co-transduced with HOXA9 and the MH1-e and transplanted into the tail vein of lethally irradiated recipient mice, the transduced HSPCs developed AML. In contrast, HSPCs co-transduced with HOXA9 and MH1-c remained healthy over one year (Figure 6I) , without any detectable GFP + RFP + cells in BM when they were sacrificed.
All mice transplanted with HSPCs expressing NUP98-HOXA9 and MH1-c stayed healthy and there was no detectable GFP + RFP + cells in BM, while mice transplanted with HSPCs co-transduced with NUP98-HOXA9 and the empty control vector (MH1-e) developed myeloproliferative disease and splenomegaly (Figure 6J) . Taken together, these findings show that active SMAD4 that can freely translocate to the nucleus of HSPCs in vivo can prevent or profoundly delay the initiation of malignant transformation. 
DISCUSSION
Several conserved signaling pathways have emerged as important regulatory circuits to govern fate options of hematopoietic stem cells (HSCs), including Winglesstype (Wnt), 32 Notch, 33 Sonic hedgehog (Shh) 34 and Smad pathways. 31 Importantly, while these signaling pathways control HSCs self-renewal, they are often dysregulated in leukemia and during leukemogenesis. 35 The Wnt/β-Catenin pathway has for example recently been shown to play an important role for HOXA9-mediated transformation of HSCs in AML. 36 Overall, our findings support the concept that SMAD4 is also a critical regulatory molecule involved in transformation of primitive hematopoietic cells and growth maintenance of leukemia stem cells.
In this study, we used an inducible Smad4 knockout (Smad4 -/-) mouse model, 29 SMAD4 is a key molecule in the TGF-β signaling pathway where its role upon complex formation with activated receptor Smads is to translocate to the nucleus 37 and regulate gene expression involved in cell cycle and apoptosis. 11 Therefore we first wanted to address if the complex between SMAD4-HOXA9 could block the SMAD4 signaling and consequently SMAD4-induced differentiation/apoptosis of primitive hematopoietic cells transduced with HOXA9 or NUP98-HOXA9. This hypothesis was plausible since Smad4 -/transduced cells show increased immortalization compared to Wt transduced cells. However, in our investigation, we discovered that the canonical function of SMAD4 was not directly involved in this phenotype. 
First of all, our previous study on normal BM shows that Smad4 signaling does not induce differentiation/apoptosis of primitive hematopoietic cells. This is evident since
Smad4 -/-BM (untransduced cells) generated normal numbers of CFU-GM colonies when cultured in semisolid medium showing that the clonogenicity and proliferation of hematopoietic stem and progenitor cells was unaffected by the Smad4 deficiency. 29 Secondly, when we used TGF-β receptor kinase inhibitors to block TGFβ /Activin receptors and therefore blocking pathways activating Smad4 signaling, we could not observe as much increase in immortalization of Wt primitive hematopoietic cells transduced with HOXA9 or NUP98-HOXA9 as was observed for Smad4 -/cells transduced with the same oncogenes.
Finally, other fusion proteins, like TEL-AML1 38 and AML1-EVI1, [39] [40] [41] have been described to bind to SMAD3 and impair TGF-β signaling and apoptosis of transduced hematopoietic stem cells in vitro. Therefore primitive hematopoietic cells transduced with these oncogenes are insensitive to recombinant TGF-β. In contrast, the TGF-β signaling was not impaired in hematopoietic cells expressing HOXA9 or NUP98-HOXA9 oncogenes, since we clearly observed that transduced HSPCs were sensitive to TGF-β growth inhibition when recombinant TGF-β was supplemented in the medium.
All these findings suggest that SMAD4-HOXA9 cannot block the SMAD4 signaling and consequently SMAD4-induced differentiation/apoptosis of primitive hematopoietic cells transduced with HOXA9 or NUP98-HOXA9. To define the mechanism, we used microscopy after immunostaining and observed that in Smad4 -/cells, the SMAD4 molecule is non-existing and simultaneously the stabilization of HOXA9 does not take place leading to increased HOXA9 in the nucleus, greater activity on target genes and amplified immortalization/transformation of hematopoietic progenitors. Therefore the SMAD4-HOXA9 complexes accumulate in the cytoplasm, suggesting that the role of SMAD4 is to stabilize HOXA9 to the cytoplasm and consequently restrain HOXA9 activity in the nucleus of primitive hematopoietic cells at moderate levels (Figure 7A, leukemia mechanism) .
In our study, the cytosolic presence of HOXA9 was observed in early-passage progenitors (immortalized 2 or 3 weeks in vitro). This is corroborated by previous experiments showing also predominant presence of HOXA9 in the cytoplasm of For personal use only. on November 16, 2017. by guest www.bloodjournal.org From hematopoietic stem and primitive progenitor cells. 42 AML blasts are generated from the transformation of primitive hematopoietic cells. Interestingly we observed that both murine and human leukemic cells predominantly expressed SMAD4 and HOXA9 in the cytoplasm and importantly HOXA9 was reported to reside principally in the cytosol of human AML cells. 43 However, nuclear localization of HOXA9 has been observed in cell lines, like in HOXA9HF1 cells, a HOXA9-immortalized cell line 44 or in the human myelomonocytic leukemia U-937 cell line, known to express HOXA9. 42 Therefore, we maintained NUP98-HOXA9-transduced cells over three months in liquid culture in vitro to establish a cell line that has >95% blast morphology and observed that HOXA9 was more expressed in the nucleus (Supplementary Figure 17) . It is therefore possible that the cytosolic expression of HOXA9 is specific to early-transduced primitive hematopoietic cells and that the HOXA9 shift toward the nucleus as the cells become more established in vitro.
The lack of leukemogenesis in TGF-β signaling-deficient mice models 29, [45] [46] [47] suggests that loss of TGF-β responsiveness is more important for progression rather than initiation of leukemogenesis. However, TGF-β is believed to be an important player in leukemogenesis since different mechanisms rendering loss of TGF-β responsiveness have been demonstrated in leukemic cells. 21 Loss-of-function mutations that disrupt the TGF-β pathway involving the Smad4 gene 23, 24 or the TGFBR2 gene 25, 26 have been reported in patients with AML. Using ultra-dense array comparative genomic hybridization on 86 AML genomes, 18 copy number alterations (CNAs) regions were found recurrently altered and interestingly one of these CNAs represents the deletion of the Smad4 gene, 27 demonstrating that Smad4 is an AML-associated gene. This relates SMAD4-HOXA9 interaction to potentially relevant biology, where alteration in expression of Smad4 gene would disrupt interaction of SMAD4 with HOXA9 and then augment the activity of HOXA9.
In myeloid leukemic cells, autocrine TGF-β and/or its Smad signals controls the ability of leukemic cells to respond to various differentiation inducers, suggesting that this pathway plays a role in determining the cell fate of leukemic cells. 22 In that case, changing the subcellular distribution of endogenous SMAD4 protein through counteracting the stabilization introduced by high levels of HOXA9 in primitive For personal use only. on November 16, 2017. by guest www.bloodjournal.org From hematopoietic cells would provide a relevant mechanism to induce differentiation/apoptosis and block expansion of transformed primitive hematopoietic cells (Figure 7B, leukemia treatment) . The co-expression of a truncated SMAD4 (MH1c) which corresponds to the MH1 part of the SMAD4 protein that binds to the HOXA9 homeodomain 28 blocks the interaction between endogenous SMAD4 and HOXA9.
Disruption of SMAD4 stabilization is confirmed by robust nuclear translocation of the SMAD4 protein, which automatically activates target genes of the TGF-β pathway and promotes apoptosis. The activation of TGF-β signaling considerably affects immortalization of primitive hematopoietic cells expressing the oncogene in vitro.
Furthermore we demonstrate that expression of a competitor molecule (MH1-c) leads to a loss of leukemia stem cells and blocks the development of leukemia in vivo.
Different studies described interactions between several other HOX and SMAD
proteins, [48] [49] [50] suggesting that the mechanisms behind this are probably complex.
Importantly, the specific portion of SMAD4 (MH1-c) encodes a peptide of 20 amino acids (127-147 of SMAD4) which correspond to the region within the MH1 aminoterminus of SMAD4 (101-148 of SMAD4) that has been described in vitro to interact with HOXA9. 28 However, while we clearly describe that the truncated SMAD4 affects the subcellular distribution of endogenous SMAD4 protein leading to activation of TGFβ signaling, Wang et al. reported that this truncated SMAD4 blocks the immortalization capability of HOXA9 by repressing the DNA binding activity of HOXA9 on its target genes. 28 We believe that both mechanisms are cooperative as we also observed downregulation of HOXA9 targets involved in BM transformation in Wt cells transduced with MH1-c (Supplementary Figure 18) . Importantly, our study shows for the first time that the TGF-β and the HOXA9 pathways as respectively negative and positive regulators of primitive hematopoietic cells expansion in normal condition (normal). Under forced expression of HOXA9 in Wt cells, SMAD4 stabilizes HOXA9 to the cytoplasm and therefore protects primitive hematopoietic cells against increased nuclear activation by HOXA9. In Smad4 -/primitive hematopoietic cells this protective mechanism can not be For personal use only. on November 16, 2017. by guest www.bloodjournal.org From operated, leading to increased concentration of HOXA9 in the nucleus, increased transcriptional activation by HOXA9 in primitive hematopoietic cells is increased making them vulnerable to leukemia transformation (leukemia mechanism). (B) Reactivation of the Smad pathway ensues upon expression of a 20aa peptide mimicking a small portion of the MH1 domain by releasing the SMAD4 to activate its targets and to induce apoptosis (leukemia treatment).
